Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $835000.0.

  • 4D Molecular Therapeutics' Non-Current Deffered Revenue fell 3476.56% to $835000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $835000.0, marking a year-over-year decrease of 3476.56%. This contributed to the annual value of $1.1 million for FY2024, which is 874.49% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $835000.0 for Q3 2025, which was down 3476.56% from $219000.0 recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Non-Current Deffered Revenue high stood at $11.7 million for Q1 2021, and its period low was $219000.0 during Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' median Non-Current Deffered Revenue value was $1.1 million (recorded in 2023), while the average stood at $1.8 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 8493.58% in 2022, then skyrocketed by 5560.8% in 2024.
  • 4D Molecular Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $2.5 million in 2021, then tumbled by 56.8% to $1.1 million in 2022, then fell by 9.67% to $972000.0 in 2023, then grew by 8.74% to $1.1 million in 2024, then fell by 21.0% to $835000.0 in 2025.
  • Its Non-Current Deffered Revenue stands at $835000.0 for Q3 2025, versus $219000.0 for Q2 2025 and $434000.0 for Q1 2025.